Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA: 688076)

Market Cap	13.02B
Revenue (ttm)	1.46B
Net Income (ttm)	348.25M
Shares Out	219.78M
EPS (ttm)	1.57
PE Ratio	37.79
Forward PE	30.81
Dividend	0.40 (0.68%)
Ex-Dividend Date	Sep 10, 2024

Volume	2,332,586
Open	60.58
Previous Close	61.03
Day's Range	58.67 - 60.98
52-Week Range	29.60 - 81.50
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Jiangsu Sinopep-Allsino Biopharmaceutical

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and unde...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,545
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688076

Financial Performance

In 2023, 688076's revenue was 1.03 billion, an increase of 58.69% compared to the previous year's 651.29 million. Earnings were 162.94 million, an increase of 26.20%.